💉 MMR Contraindications in Immunocompromised Patients Simulator

Immunocompetent Patients — Live MMR Is Safe

A healthy immune system clears attenuated MMR virus without disease.

• 97%: MMR efficacy, 2 doses (measles protection)
• Live-attenuated: Vaccine type (weakened but replicating)
• 12–15 mo: Standard schedule (then 4–6 yr booster)
• <0.01%: Serious reaction rate (in healthy hosts)

Why live vaccines need working immunity

Attenuated virus still replicates briefly before clearance.

Immune clearance timeline

T-cells and antibodies contain the strain within days.

Baseline screening before dosing

History review confirms no suppression before vaccination.

Chemotherapy Patients — Live Vaccine Contraindicated

Cytotoxic drugs suppress lymphocytes, blocking safe viral clearance.

• During Rx: Contraindication window (plus 3–6 months after)
• High: Neutrophil suppression (chemo cycle dependent)
• 3–6 mo: Post-chemo wait (immune recovery needed)
• Disseminated: Risk if given (vaccine-strain infection)

Cytotoxic suppression mechanism

Chemo kills dividing lymphocytes needed to clear virus.

Timing around treatment cycles

Live vaccines are deferred through active cycles entirely.

Alternatives during suppression

Household contacts get vaccinated instead — cocooning strategy.

HIV With Low CD4 — Disseminated Infection Risk

Low CD4 counts cannot contain the attenuated measles strain.

• ≥200 /µL: CD4 safety threshold (and ≥15% for children)
• <200 /µL: High-risk threshold (live MMR contraindicated)
• Months: ART recovery timeline (to rebuild CD4 count)
• Severe: Disseminated measles risk (can be fatal)

CD4 threshold for live vaccines

Guidelines set 200 cells/µL as the safety cutoff.

Why disseminated infection occurs

Uncontrolled replication spreads vaccine-strain virus systemically.

ART as the recovery pathway

Antiretroviral therapy rebuilds CD4 before vaccination resumes.

Transplant Recipients — Delayed Vaccination Algorithm

Immunosuppressive regimens after transplant require a scheduled delay.

• ≥2 yrs: Solid organ wait (post-transplant minimum)
• ≥24 mo: Stem cell wait (off immunosuppression)
• Extends delay: GVHD complication (graft-versus-host disease)
• ≥4 weeks: Pre-transplant window (before immunosuppression starts)

Fixed algorithmic wait periods

Protocols set minimum delays regardless of symptoms.

Pre-transplant vaccination push

Live vaccines are front-loaded weeks before transplant.

Monitoring immunosuppressive taper

Drug dose reduction is tracked before rechallenge.

Immune Recovery — Vaccination Becomes Safe Again

Restored CD4 and lymphocyte counts reopen the vaccination window.

• Lab-verified: Recovery confirmation (CD4 / counts checked)
• High: Re-vaccination success (once thresholds met)
• Often needed: Repeat dosing (prior immunity may wane)
• 4–8 wks: Follow-up titer check (confirms seroconversion)

Confirming true recovery

Lab values must clear thresholds, not just time elapsed.

Re-vaccination protocol

MMR is re-dosed once immune competence is confirmed.

Long-term surveillance

Titers are rechecked to confirm lasting protection.